<DOC>
	<DOCNO>NCT02461992</DOCNO>
	<brief_summary>An open-label , single dose pharmacokinetic study Xyntha ( Moroctocog Alfa ( AF-CC ) , Recombinant Factor VIII ) male Chinese subject hemophilia A</brief_summary>
	<brief_title>Study PF-05208756 , Moroctocog Alfa ( AF-CC ) , Xyntha For Male Chinese Subjects With Hemophilia A</brief_title>
	<detailed_description>The purpose study obtain pharmacokinetic profile FVIII : C Xyntha administration Chinese patient severe hemophilia A , support continue registration Xyntha China</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible enrollment study : 1 . Male Chinese subject 6 year old ( weight &gt; 20 kg ) severe hemophilia A ( factor VIII activity &lt; 1 % ) previously treat &gt; 150 exposure day FVIIIcontaining product . 2 . Subjects receive infusion FVIII product least 3 day ( least 72 hour ) administration Xyntha Day 1 . 3 . Subjects must non bleed state administration Xyntha Day 1 . 4 . Evidence personally legally acceptable representative ( legally acceptable representative applicable pediatric subject ) sign date informed consent document indicate subject inform pertinent aspect study . 5 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Subjects follow characteristics/conditions include study : 1 . Current FVIII inhibitor history FVIII inhibitor ( define &gt; upper limit normal ( ULN ) local report laboratory ) . 2 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) clinical finding Screening . 3 . Diagnosed bleed disorder addition hemophilia A . 4 . Documented Human Immunodeficiency Virus ( HIV ) . 5 . Subjects anticipate elective surgery invasive procedure within 1 month follow study entry . 6 . Treatment immunomodulatory therapy within 30 day 5 half life whichever longer , prior study entry plan use duration study participation . 7 . Subjects know hypersensitivity active substance excipients Xyntha . 8 . Subjects know hypersensitivity Chinese Hamster Ovary cell ( CHO cell ) proteins . 9 . Subjects ANY follow abnormality clinical laboratory test screen , assess study specific laboratory confirm single repeat , deem necessary : significant hepatic renal impairment ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 x ULN , total bilirubin &gt; 2 x ULN serum creatinine &gt; 2 x ULN ) , prothrombin time &gt; 1.5 x ULN , platelet count &lt; 80,000 L. Subjects Gilbert 's disease may enrol . 10 . Unwilling unable follow term protocol . 11 . Any condition may compromise subject 's ability comply and/or perform study related activity pose clinical contraindication study participation , opinion investigator sponsor . 12 . A positive urine drug screen . 13 . History regular alcohol consumption exceed 14 drinks/week ( 1 drink = 5 ounce ( 150 mL ) wine , 12 ounce ( 360 mL ) beer , 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . 14 . Treatment investigational drug within 30 day 5 half life precede Day 1 , whichever longer . 15 . Screening supine blood pressure 140 mm Hg ( systolic ) 90 mm Hg ( diastolic ) , follow least 5 minute supine rest . If blood pressure ( BP ) 140 mm Hg ( systolic ) 90 mm Hg ( diastolic ) , BP repeat two time average three BP value use determine subject 's eligibility . 16 . Screening supine 12 lead ECG demonstrate QTcF &gt; 450 QRS interval &gt; 120 msec msec . If QTcF exceed 450 msec , QRS exceed 120 msec , ECG repeat two time average three QTcF value use determine subject 's eligibility . 17 . Blood donation ( exclude plasma donation ) approximately 500 mL within 56 day prior dose . 18 . History sensitivity heparin heparin induce thrombocytopenia . 19 . Unwilling unable comply Lifestyle Guidelines describe protocol . 20 . Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised Investigator , subject Pfizer employee directly involve conduct study . 21 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . 22 . Subjects history infection within 1 week prior study entry . 23 . Male subject partner currently pregnant male subject able father child unwilling unable use highly effective method contraception outline protocol duration study least 28 day last dose investigational product .</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>FVIII activity</keyword>
</DOC>